Gamida Cell Ltd (GMDAQ)

[midastouch017]

Don't 'Cell' Gamida, Buy It

Gamida Cell (GMDA) - Get Report is a biotechnology company that is using cell therapy to address blood cancers and serious blood disorders. Preliminary data has been robust and the company has already indicated that it met three secondary endpoints.

The company expected to report a full peer-reviewed data set in the first half of 2021. It originally intended to apply for a biological license application (BLA) on a rolling basis, but the FDA is requesting details about its planned commercial manufacturing sites.

GMDA2021
Dan Rosenblum, the biotechnology expert at SharkInvesting.com, tells me, “What is really exciting about GMDA is the update on Natural Killer Cell Therapy GDA-201. In an oral presentation at the recent American Society of Hematology (ASH) 62nd Annual Meeting, it was shown that GDA-201 was well tolerated and no dose-limiting toxicities were observed in the Phase 1 clinical study. GDA-201 demonstrated significant clinical activity in patients with non-Hodgkin lymphoma, with 13 complete responses and one partial response observed in 19 patients, for a response rate of 74%. ... Basically, the Natural killer cell technology produced cures in three out of four lymphoma patients.”


The company is a long way from final approval in late 2021, but the innovation of cell therapy is already attracting attention and there should be updates on progress in the first half of 2021 to drive the stock. GMDA is currently the largest holding in the ARK Israel Innovative Technology ETF at 247,218 shares.

I will be actively trading these stocks as they develop, but I feel that they have longer-term potential in the year ahead that will help to provide good support.

DePorre writes a daily column for Real Money, TheStreet’s premium site for active traders. Click here to learn more and get great columns, commentary and trade ideas from Jim Cramer, Helene Meisler, Mark Sebastian, Paul Price, Doug Kass, and others.

At the time of publication, DePorre was long NNDM, XERS, BRGGF, PEIX, GMDA.

Please note that due to factors including low market capitalization and/or insufficient public float, we consider these names to be small-cap stocks. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.

Coronavirus Market Update: Sign up for TheStreet's Coronavirus Market Update newsletter and get the latest market headlines delivered to your inbox daily.

TAGSNATURAL GASSTOCKS
James "Rev Shark" DePorre
BY JAMES "REV SHARK" DEPORRE

https://finance.yahoo.com/m/98e81991-041f-3ec0-bf25-35ea4723b522/5-low-priced%2C-small-cap.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo